Every IPO moves through five stages. Bellipo moves BBTX the moment its record changes.
RADAR No terms yet Oct 9, 2026 READY Terms set Oct 26, 2026 PINGNOW Priced Priced $16.00 · Oct 30, 2026 STRIKE First trade Expected Nov 3, 2026 ORBIT Trading On the record Priced on Oct 30, 2026 at $16.00 a share — the midpoint of the $15–$17 range — upsized to a final 10,555,555 shares. First trade expected Nov 3, 2026. Next on the record Quiet period ends (est. Nov 24, 2026) · First quarterly report (10-Q) (est. Dec 14, 2026) · Lock-up ends (not dated)Bambusa acquired both of its lead drugs from BioNTech's Chinese research unit less than three years ago.
Share this factBambusa Therapeutics started on March 14, 2024 and is based in Boston. It does not invent its drugs from scratch: it acquired its two lead drugs, BBT001 and BBT002, from BioNTech (Zhuhai) Pharmaceuticals R&D, a BioNTech subsidiary formerly known as Biotheus. Each drug is a bispecific antibody, built to block two disease signals at once and to last longer between doses than today's antibody drugs. It had 30 full-time employees as of September 30, 2026 and has no product sales.
COMPANY PROFILE Legal name Bambusa Therapeutics, Inc. Incorporated Delaware Founded March 14, 2024 Headquarters 22 Boston Wharf Road, Floor 7, Boston, MA 02210 Website bambusatx.com Employees 30 Industry Biological products (SIC 2836) Stage Clinical stage Where the drugs came from Acquired from BioNTech (Zhuhai) Pharmaceuticals R&D (formerly Biotheus) Revenue, last 12 months $0 Net income (loss), 12 months to Jun 30, 2026 ($48.7M) Exchange · ticker Nasdaq · BBTX Exchange tier Nasdaq Global Market Every field from the S-1/A and the record, each with its source on tap.Two drugs carry the company. Each one combines two targets that already have approved drugs, so the bet is not whether the targets work, but whether hitting both at once, with fewer doses, works better.
BBT001 PHASE 2B PLANNED TREATS Atopic dermatitis (eczema) and other itchy skin diseases HOW IT WORKS Bispecific antibody blocking IL-4Rα and IL-31: inflammation and itch ALREADY APPROVED ON THESE TARGETS Dupixent (IL-4Rα) and Nemluvio (IL-31) Next: start-up of a Phase 2b dose-ranging trial of an injectable form, by the end of 2026. BBT002 PHASE 1 · PHASE 2A (CHINA) TREATS COPD and chronic sinusitis with nasal polyps HOW IT WORKS Bispecific antibody blocking IL-4Rα and IL-5, both main paths of Type 2 inflammation ALREADY APPROVED ON THESE TARGETS Dupixent (IL-4Rα) and Nucala (IL-5) Trials: global Phase 1 in COPD (US, Australia, Europe, Georgia, New Zealand); Phase 1/2a in COPD and Phase 2a in nasal polyps, both in China. BBT003 · BBT004 PRECLINICAL BBT003 TL1A × IL-23p19 for Crohn's disease and ulcerative colitis. Clinic by end of 2026. BBT004 Dual B-cell depletion for autoantibody-driven disease. Clinic by end of 2027. WHY IT MATTERS Both are years from data. Today the stock is priced on BBT001 and BBT002. EXHIBIT 1 Only BBT001 is heading into Phase 2b. Nothing is near approval yet. Discovery Preclinical Phase 1 Phase 2 Phase 3 BBT001 Atopic dermatitis BBT002 COPD, nasal polyps BBT003 Crohn's, colitis BBT004 Autoimmune disease Source: Company S-1/A (Oct 26, 2026).The dates ahead, the money, the deal, the Bellipo Demand Index (BDI), the risks and our bottom line.
FREE BETA · NO CARD · OPENS DEC 1, 2026| Oct 9, 2026 | S-1 · registration statement | 0001628280-26-065557 |
| Oct 26, 2026 | S-1/A · terms set | 0001628280-26-067119 |
| Oct 27, 2026 | 8-A12B · exchange registration | 0001628280-26-067557 |
| Oct 29, 2026 | CERT · Nasdaq listing certification | 0001354457-26-001035 |
| Oct 30, 2026 | Company pricing release · final terms | on the record |
BD·BBTX·2026 · v1.3 · every figure cited · View the full source record
Every figure in this dossier traces to the filings below; figures Bellipo computed are labelled as Bellipo arithmetic.
Every figure comes from the S-1 and carries its printed page. Nothing is estimated. Below is each stored row and its source, so you can check it yourself. How we grade sources.
Terms of record · Issuer release Accepted Terms| Field | Value | Source |
|---|---|---|
| Terms of record | Issuer release | Issuer release via prnewswire.com · retrieved Oct 30, 2026 · open release |
| Marketed range | $15.00–$17.00 | Range as disclosed in the registration statement. A marketed band is not terms of record. |
| Shares offered | 10,555,555 | Base offering as disclosed in the filing. Excludes any underwriter option unless stated in the body. |
| SEC identifier | 0002044950 | Central Index Key. View this company's filings on EDGAR. |
| Registration filing | on file | Open the registration statement |
| Field | Value | Source |
|---|---|---|
| Offer price | $16.00 | Final price as filed. Priced Oct 30, 2026. |
| Pricing source | EDGAR_424B4 | The channel that supplied the price. Recorded for audit; it does not override the provenance tier. |
| Score frozen | 30 Oct 2026 · 16:30 ET | The instant the demand read was locked. It is not restated after the First Print. Methodology. |
| Dossier revised | Nov 3, 2026 | Sections are versioned. Corrections are filed publicly rather than edited away. |
Not yet traded. This section fills in when the First Print is established.
LockupNo lock-up length is on file for this offering.
Dossiers like this one, the Lifecycle Engine and the Bellipo Demand Index (BDI) for every IPO. Free account, no card.
FREE BETA · OPENS DEC 1, 2026